H.C. Wainwright upgraded MiNK Therapeutics (INKT) to Buy from Neutral with an unchanged price target of $35 post the Q2 report. The firm sees the company’s Phase 2 gastric cancer data later this year as a “significant catalyst” for the shares. The majority of patients in the Phase 2 gastric study are now enrolled and initial efficacy data is expected in the back half of the year, the analyst tells investors in a research note. H.C. Wainwright points out MiNK shares are now well below its price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK Therapeutics Reports Q2 2025 Milestones and Financials
- MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year
- Mink Therapeutics, Inc. (INKT) Q2 Earnings Cheat Sheet
- H.C. Wainwright downgrades MiNK Therapeutics after 400% rally
- MiNK Therapeutics downgraded to Neutral from Buy at H.C. Wainwright